Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 11.11%, which has investors questioning if this is right time ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most prevalent and deadliest forms of ovarian cancer. Their work is published in ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. As we near the end of 2024, CURE is looking back at ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.